تحت رعاية سموّ الشيخ خالد بن محمد بن زايد آل نهيان، ولي عهد أبوظبي رئيس المجلس التنفيذي لإمارة أبوظبي
Under the Patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council
Merck & Co: Merck to buy Prometheus Biosciences for about $11 bln, ET HealthWorld
Prometheus had a market capitalisation of $5.42 billion at Friday's close. Merck Merck has been looking for deals to protect itself from eventul revenue loss as patents on its cancer immunotherapy keytruda begin to expire towards the end of the decade.
The joint statement said that Merck, through one of its subsidiaries, will pay $$200 per share for the biotechnology company that specializes in product for treatment of immunological diseases. That represents a 75 per cent premium to the $114.01 closing price for Prometheus shares on Friday.